ATE302605T1 - Tazaroten und uvb-phototherapie zur behandlung von psoriasis - Google Patents

Tazaroten und uvb-phototherapie zur behandlung von psoriasis

Info

Publication number
ATE302605T1
ATE302605T1 AT98930109T AT98930109T ATE302605T1 AT E302605 T1 ATE302605 T1 AT E302605T1 AT 98930109 T AT98930109 T AT 98930109T AT 98930109 T AT98930109 T AT 98930109T AT E302605 T1 ATE302605 T1 AT E302605T1
Authority
AT
Austria
Prior art keywords
tazarotene
psoriasis
treatment
uvb phototherapy
effective amount
Prior art date
Application number
AT98930109T
Other languages
English (en)
Inventor
John Sefton
Deborah A Lew-Kaya
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE302605T1 publication Critical patent/ATE302605T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
AT98930109T 1997-06-11 1998-06-10 Tazaroten und uvb-phototherapie zur behandlung von psoriasis ATE302605T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4938597P 1997-06-11 1997-06-11
PCT/US1998/011989 WO1998056375A1 (en) 1997-06-11 1998-06-10 Tazarotene and uvb phototherapy treatment for psoriasis

Publications (1)

Publication Number Publication Date
ATE302605T1 true ATE302605T1 (de) 2005-09-15

Family

ID=21959543

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98930109T ATE302605T1 (de) 1997-06-11 1998-06-10 Tazaroten und uvb-phototherapie zur behandlung von psoriasis

Country Status (8)

Country Link
EP (1) EP1001770B1 (de)
JP (1) JP2002504121A (de)
AT (1) ATE302605T1 (de)
AU (1) AU726141B2 (de)
CA (1) CA2293303A1 (de)
DE (1) DE69831336T2 (de)
ES (1) ES2247699T3 (de)
WO (1) WO1998056375A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions
US6290713B1 (en) 1999-08-24 2001-09-18 Thomas A. Russell Flexible illuminators for phototherapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA954599B (en) * 1994-06-07 1996-01-26 Allergan Inc Stable gel formulation for topical treatment of skin conditions

Also Published As

Publication number Publication date
AU7957598A (en) 1998-12-30
CA2293303A1 (en) 1998-12-17
WO1998056375A1 (en) 1998-12-17
ES2247699T3 (es) 2006-03-01
DE69831336D1 (de) 2005-09-29
JP2002504121A (ja) 2002-02-05
EP1001770B1 (de) 2005-08-24
EP1001770A1 (de) 2000-05-24
AU726141B2 (en) 2000-11-02
DE69831336T2 (de) 2006-06-22

Similar Documents

Publication Publication Date Title
ATE254447T1 (de) Verfahren zur phototherapeutischen behandlung von proliferativen hauterkrankungen
DE69510696D1 (de) 2-(2-amino-3-methoxyphenyl)-4-oxo-4h-(1)-benzopyran für die behandlung von proliferativer erkrankungen
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
ATE198044T1 (de) Hydroperoxeicosatetraensäure derivate enthaltende zusammensetzungen und verfahren zur verwendung zur behandlung des trockenen auges
DE69902131D1 (de) Kosmetische und/oder dermatologische Zusammensetzung enthaltend Salicylsäure oder ihre Derivate und ihre Verwendung
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
ATE186834T1 (de) Verwendung von wirksamen mengen von aktiven stoffen zur behandlung von mischhaut
ATE321548T1 (de) Verwendung von statin zur behandlung von hauterkrankungen
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
ATE249220T1 (de) Verwendung von piperin und derivate davon zur behandlung von hautpigmentierungstörungen und hautkrebs
EP0610368A4 (de) Behandlung von akne oder von folliculitis barbae.
KR920700634A (ko) 좌창 또는 건선 피부병을 치료하는 방법 및 여기에 사용되는 조성물
TW200505473A (en) Compositions and methods for treatment of psoriasis
ATE218862T1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von hautinfektionen
ATE311871T1 (de) Verwendung von zinksalzen der konjugierten linoleinsäuren zur behandlung von hautkrankheiten
DE69902520D1 (de) Verwendung von selegilin oder desmethylselegilin zur behandlung von wunden, verbrennungen und hautschäden
ATE160088T1 (de) Topische wässrige gele oder suspension auf basis von pulverisiertem vulkanischen oder diagenischem minerale
DE69229780D1 (de) Zusammensetzung und methode zur behandlung von störungen in form von depigmentierung
ATE179594T1 (de) Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie
DE69822276D1 (de) Kräuter formulierung mit therapeutischer und kosmetischer verwendung zur behandlung von allgemeinen hauterkrankungen
DE69503724D1 (de) L-Carnitin-Salz, dieses enthaltende kosmetische und pharmazeutische Zusammensetzungen zur Behandlung von Dermatosen
DE69932922D1 (de) Verwendung von alkansäuren-enthaltenden zusammensetzungen zur behandlung von nagelpilz-erkrankungen
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
DE69831336D1 (de) Tazaroten und uvb-phototherapie zur behandlung von psoriasis
FR2786100B1 (fr) Nouvelle application therapeutique de la nicergoline

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties